Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.2K
Skin Cancer01:30

Skin Cancer

6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K
Mutations01:35

Mutations

44.9K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.9K
Mutations01:39

Mutations

95.1K
Overview
95.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust tauopathy and memory deficits in a mouse model constitutively overexpressing human P301L MAPT.

Neurobiology of disease·2026
Same author

Clinical Applications of Reflectance Confocal Microscopy in Paediatric Dermatology: A Systematic Review.

Experimental dermatology·2026
Same author

Human Genome Promise-Are We There Yet?

JAMA dermatology·2026
Same author

A dating app for extracellular adhesion proteins.

Cell genomics·2026
Same author

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

BMJ oncology·2026
Same author

Geographic variation in the impact of novel melanoma therapies on mortality.

Journal of the American Academy of Dermatology·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K

Somatic driver mutations in melanoma.

Bobby Y Reddy1, David M Miller1,2, Hensin Tsao1

  • 1Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Cancer
|May 26, 2017
PubMed
Summary
This summary is machine-generated.

Melanoma research identifies key driver mutations, distinguishing them from passenger mutations. This distinction is crucial for developing effective targeted therapies against this complex cancer.

Keywords:
driver mutationsgeneticsimmune therapymelanomatargeted therapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Melanoma exhibits a high somatic mutational burden, complicating the understanding of its pathogenesis.
  • Next-generation sequencing has revealed numerous genomic alterations, but their clinical significance remains largely uncharacterized.
  • Differentiating neutral passenger mutations from functionally significant driver mutations is essential for advancing melanoma treatment.

Purpose of the Study:

  • To review current literature on significant somatic driver mutations in melanoma.
  • To discuss the implications of these driver mutations for therapeutic strategies.
  • To highlight advances in genomic data analysis for distinguishing driver from passenger mutations.

Main Methods:

  • Literature review of genomic research in melanoma.
  • Analysis of next-generation sequencing data.
  • Focus on distinguishing driver mutations from passenger mutations.

Main Results:

  • Identified key somatic driver mutations implicated in melanoma progression.
  • Emphasized the critical role of driver mutations in tumor development.
  • Highlighted the clinical relevance of genomic alterations.

Conclusions:

  • Distinguishing driver mutations is vital for developing targeted melanoma therapies.
  • Advances in genomic analysis are improving the identification of actionable mutations.
  • Understanding melanoma genomics offers promising avenues for novel treatments.